missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human Pro-EGF (aa 21-1023) Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
POA
Specifications
| Accession Number | CAA28240 |
|---|---|
| For Use With (Application) | Bioactivity |
| Gene ID (Entrez) | 1950 |
| Molecular Weight (g/mol) | M.W. (Observed): 138-145 kDa, reducing conditions; M.W. (theoretical): 112 kDa |
| Name | Pro EGF aa 21-1023 |
Description
Measured in a cell proliferation assay using Balb/3T3 mouse embryonic fibroblast cells. Rubin, J.S. et al. (1991) Proc. Natl. Acad. Sci. USA 88:415. The ED50 for this effect is 1-5 ng/mL.Specifications
| CAA28240 | |
| 1950 | |
| Pro EGF aa 21-1023 | |
| Mouse myeloma cell line, NS0-derived human EGF protein Met1-Arg1023, with a C-terminal 6-His tag | |
| <0.01 EU / 1 μg of the protein by the LAL method. | |
| Unconjugated | |
| >90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| Bioactivity | |
| M.W. (Observed): 138-145 kDa, reducing conditions; M.W. (theoretical): 112 kDa | |
| 25 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution. | |
| EGF | |
| Recombinant | |
| EGF |